Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease
Hellenbrand, W.; Koch, J.; Harder, T.; Bogdan, C.; Heininger, U.; Tenenbaum, T.; Terhardt, M.; Vogel, U.; Wichmann, O.; von Kries, R. · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · 2015 · Heft 10 · S. 1314 bis 1343
Bibliografische Angaben
Zusammenfassung
In December 2013 Bexsero® became available in Germany for vaccination against serogroup B meningococci (MenB). In August 2015 the German Standing Committee on Vaccination (STIKO) endorsed a recommendation for use of this vaccine in persons at increased risk of invasive meningococcal disease (IMD). This background paper summarizes the evidence underlying the recommendation. Bexsero® is based on surface protein antigens expressed by about 80 % of circulating serogroup B meningococci in Germany. The paper reviews available data on immunogenicity and safety of Bexsero® in healthy children and adolescents; data in pe…
